Literature DB >> 17893655

Two novel PAX6 mutations identified in northeastern Chinese patients with aniridia.

Huiping Yuan1, Yang Kang, Zhenqbo Shao, Yuanyuan Li, Guoyu Yang, Na Xu.   

Abstract

PURPOSE: The PAX6 gene encodes a transcriptional regulator involved in oculogenesis and other developmental processes such as aniridia, a congenital condition characterized by the underdevelopment of the eye's iris. Aniridia may be broadly divided into hereditary and sporadic forms. The function of the PAX6 gene in these two forms of aniridia is still poorly defined. Therefore, we carried out a mutation analysis of the PAX6 gene in northeastern Chinese families with aniridia to identify the role of the PAX6 gene in hereditary aniridia.
METHODS: Five aniridia patients from two northeastern Chinese families (Family 1 and Family 2) underwent full ophthalmologic examinations. Genomic DNA was prepared from venous leukocytes from these five patients, 10 non-carriers in these two families, as well as 100 healthy normal controls. The coding regions of PAX6 were analyzed by PCR amplification, direct sequencing and allele-specific cloning sequencing. RESULTS We identified two novel PAX6 mutations. The first is a 9 base pair (bp) deletion in exon 5 (c.483del9) that makes a PAX6 protein with de novo in-frame deletions of aspartic acid, isoleucine, and serine at the amino acid codon positions 41-43. The second is a heterozygous mutation (IVS10+1G>A) located at the boundary of exon 10 and intron 10.
CONCLUSIONS: We identified two novel PAX6 mutations in familial aniridia from northeastern China, an ethnic group that is not well-studied. The genetic analysis confirms that these two novel mutations in PAX6 are capable of causing the classic aniridia phenotype. Therefore, by studying human familial aniridia cases, we demonstrated that PAX6 plays a role in hereditary aniridia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17893655

Source DB:  PubMed          Journal:  Mol Vis        ISSN: 1090-0535            Impact factor:   2.367


  8 in total

1.  A 556 kb deletion in the downstream region of the PAX6 gene causes familial aniridia and other eye anomalies in a Chinese family.

Authors:  Fang Cheng; Wulian Song; Yang Kang; Shihui Yu; Huiping Yuan
Journal:  Mol Vis       Date:  2011-02-10       Impact factor: 2.367

2.  PAX6 analysis of one family and one sporadic patient from southern China with classic aniridia.

Authors:  Ying Lin; Xialin Liu; Xuanwei Liang; Baoxin Li; Shuhong Jiang; Shaobi Ye; Huiqin Yang; Bingsheng Lou; Yizhi Liu
Journal:  Mol Vis       Date:  2011-11-26       Impact factor: 2.367

3.  Mutation spectrum of PAX6 in Chinese patients with aniridia.

Authors:  Xiaohui Zhang; Panfeng Wang; Shiqiang Li; Xueshan Xiao; Xiangming Guo; Qingjiong Zhang
Journal:  Mol Vis       Date:  2011-08-11       Impact factor: 2.367

4.  A recurrent PAX6 mutation is associated with aniridia and congenital progressive cataract in a Chinese family.

Authors:  Chongfei Jin; Qiwei Wang; Jinyu Li; Yanan Zhu; Xingchao Shentu; Ke Yao
Journal:  Mol Vis       Date:  2012-02-16       Impact factor: 2.367

5.  A novel PAX6 deletion in a Chinese family with congenital aniridia.

Authors:  Jian Huan Chen; Weitao Lin; Guoying Sun; Chukai Huang; Yuqiang Huang; Haoyu Chen; Chi Pui Pang; Mingzhi Zhang
Journal:  Mol Vis       Date:  2012-04-21       Impact factor: 2.367

6.  Mutation analysis of PAX6 in inherited and sporadic aniridia from northeastern China.

Authors:  Yang Kang; Ying Lin; Xue Li; Qiong Wu; Lei Huang; Qingjun Li; Qi Hu
Journal:  Mol Vis       Date:  2012-06-27       Impact factor: 2.367

7.  Eye anomalies and neurological manifestations in patients with PAX6 mutations.

Authors:  Yin-Hsuan Chien; Hsiang-Po Huang; Wuh-Liang Hwu; Yin-Hsiu Chien; Tseng-Ching Chang; Ni-Chung Lee
Journal:  Mol Vis       Date:  2009-10-22       Impact factor: 2.367

8.  Mutation analysis of paired box 6 gene in inherited aniridia in northern China.

Authors:  Peng Chen; Xinjie Zang; Dapeng Sun; Ye Wang; Yao Wang; Xiaowen Zhao; Mohan Zhang; Lixin Xie
Journal:  Mol Vis       Date:  2013-05-30       Impact factor: 2.367

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.